Matches in DBpedia 2016-04 for { <http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022474s002lbl.pdf> ?p ?o }
Showing triples 1 to 9 of
9
with 100 triples per page.
- 022474s002lbl.pdf author "Watson Pharma".
- 022474s002lbl.pdf date "2012-05-02".
- 022474s002lbl.pdf isCitedBy Emergency_contraception.
- 022474s002lbl.pdf location "Silver Spring, Md.".
- 022474s002lbl.pdf pages "4–5".
- 022474s002lbl.pdf publisher "FDA Center for Drug Evaluation and Research".
- 022474s002lbl.pdf quote "When taken immediately before ovulation is to occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy... The pharmacodynamics of ulipristal acetate depends on the timing of administration in the menstrual cycle. Administration in the mid-follicular phase causes inhibition of folliculogenesis and reduction of estradiol concentration. Administration at the time of the luteinizing hormone peak delays follicular rupture by 5 to 9 days. Dosing in the early luteal phase does not significantly delay endometrial maturation but decreases endometrial thickness by 0.6 ± 2.2 mm .".
- 022474s002lbl.pdf title "Prescribing information: Ella; 12.1 Mechanism of action".
- 022474s002lbl.pdf url "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022474s002lbl.pdf".